Abstract:Autophagy is a process of selective degradation of cellular components. Autophagy is an adaptive process in the majority of tumor cells; it provides sufficient nutrients by degrading cellular components to enhance the survival of tumors. Osteosarcoma is the most common type of primary malignant bone tumor in children and adolescents. Identification of an improved therapeutic strategy for the treatment of osteosarcoma is urgently required. Osteosarcoma has been primarily treated by chemotherapy and the phenomena of resistance to the therapy has become increasingly common. Doxorubicin (Dox) is a classic chemotherapeutic drug for the treatment of osteosarcoma, and certain studies have suggested that Dox induces autophagy. On the basis of the protective effect of autophagy for tumors, the present study investigated whether U2OS and Saos-2 osteosarcoma cells activate autophagy to reduce Dox-induced apoptosis. Dox was observed to inhibit the growth of U2OS and Saos-2 osteosarcoma cells in a concentration-dependent manner. The results of the western blot analysis demonstrated that Dox induced increased expression levels of the apoptosis-related proteins cleaved caspase-3 and cytochrome c and loss of mitochondrial membrane potential (MMP) in the U2OS and Saos-2 osteosarcoma cells. Furthermore, the results of the western blot analysis also revealed that Dox increased the expression levels of the autophagy-related protein microtubule-associated protein 1 light chain 3 and reduced those of p62 in the U2OS and Saos-2 osteosarcoma cells. In order to determine the effect of autophagy on the apoptosis induced by Dox in the U2OS and Saos-2 osteosarcoma cells, autophagy-related protein (Atg)7 small interfering (si) RNA or the autophagy inhibitor 3-methyladenine (3-MA) alone or combined with Dox was used in U2OS and Saos-2 osteosarcoma cells. The results identified that Atg7 siRNA and the autophagy inhibitor 3-MA significantly elevated the levels of growth inhibition by Dox and markedly increased the expression levels of the apoptosis-related proteins cleaved caspase-3 and cytochrome c, and reduced the levels of MMP in the U2OS and Saos-2 osteosarcoma cells, which were treated with Dox. These results indicated that autophagy was the protective mechanism used by U2OS and Saos-2 osteosarcoma against Dox-induced apoptosis. The inhibition of autophagy notably increases the levels of apoptosis induced by Dox. This suggested that Dox used in combination with autophagy inhibitors may effectively treat osteosarcoma.

CXCR4 Blockade Sensitizes Osteosarcoma to Doxorubicin by Inducing Autophagic Cell Death Via PI3K‑Akt‑mTOR Pathway Inhibition.

Chloroquine Blocks The Autophagic Process In Cisplatin-Resistant Osteosarcoma Cells By Regulating The Expression Of P62/Sqstm1

Blocking CXCR4-CARM1-YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis

Silencing Of Barkor/Atg14 Sensitizes Osteosarcoma Cells To Cisplatin-Induced Apoptosis

Autophagy prevents doxorubicin‑induced apoptosis in osteosarcoma.

Blocked Autophagy by Mir-101 Enhances Osteosarcoma Cell Chemosensitivity in Vitro

Exosomal Long Non-Coding RNA ANCR Mediates Drug Resistance in Osteosarcoma

Cyclovirobuxine D Inhibits the Growth of Osteosarcoma Cells Through the Induction of Autophagy Flux Arrest by Promoting Lysosomal Acidification

Genome-wide CRISPR Screen Identified Rad18 As a Determinant of Doxorubicin Sensitivity in Osteosarcoma

Targeting Autophagy is a Promising Therapeutic Strategy to Overcome Chemoresistance and Reduce Metastasis in Osteosarcoma

Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.

LncRNA Sox2OT-V7 Promotes Doxorubicin-Induced Autophagy and Chemoresistance in Osteosarcoma Via Tumor-Suppressive Mir-142/Mir-22

SOX2OT Variant 7 Contributes to the Synergistic Interaction Between EGCG and Doxorubicin to Kill Osteosarcoma Via Autophagy and Stemness Inhibition

The COPS3-FOXO3 positive feedback loop regulates autophagy to promote cisplatin resistance in osteosarcoma

Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways

MicroRNA-199a-5p Inhibits Cisplatin-Induced Drug Resistance Via Inhibition of Autophagy in Osteosarcoma Cells.

Hypoxia promotes drug resistance in osteosarcoma cells via activating AMP-activated protein kinase (AMPK) signaling.

Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.

Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma.

HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma

NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy